The Safety and Efficacy of Alverine in the Treatment of Cirrhotic Portal Hypertension

PHASE2/PHASE3Not yet recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

June 30, 2024

Primary Completion Date

March 31, 2025

Study Completion Date

March 31, 2025

Conditions

Hypertension, Portal

Interventions

DRUG

Alverine

180 mg/day (1 capsule orally, 3 times a day), taken continuously for 24 weeks

All Listed Sponsors

collaborator

Shanghai East Hospital

OTHER

collaborator

Daping Hospital, Army Medical Center of PLA

OTHER

lead

Shanghai Changzheng Hospital

OTHER

NCT06473493 - The Safety and Efficacy of Alverine in the Treatment of Cirrhotic Portal Hypertension | Biotech Hunter | Biotech Hunter